This study investigates the impact of short-chain fatty acids (SCFAs), specifically pentanoate and butyrate, on the anti-tumor activity of cytotoxic T lymphocytes (CTLs) and chimeric antigen receptor (CAR) T cells. In vitro treatment with these SCFAs enhanced CTL and CAR T cell function by modulating metabolic and epigenetic pathways, leading to increased production of effector molecules and improved anti-tumor activity in murine models. The findings suggest therapeutic potential for these SCFAs in cellular cancer immunotherapy.
Publisher
Nature Communications
Published On
Nov 16, 2021
Authors
Maik Luu, Zeno Riester, Adrian Baldrich, Nicole Reichardt, Samantha Yuille, Alessandro Busetti, Matthias Klein, Anne Wempel, Hanna Leister, Hartmann Raifer, Felix Picard, Khalid Muhammad, Kim Ohl, Rossana Romero, Florence Fischer, Christian A. Bauer, Magdalena Huber, Thomas M. Gress, Matthias Lauth, Sophia Danhof, Tobias Bopp, Thomas Nerreter, Imke E. Mulder, Ulrich Steinhoff, Michael Hudecek, Alexander Vise Kruna
Tags
short-chain fatty acids
pentanoate
butyrate
cytotoxic T lymphocytes
CAR T cells
cancer immunotherapy
effector molecules
Related Publications
Explore these studies to deepen your understanding of the subject.